{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:14:57Z","timestamp":1778228097875,"version":"3.51.4"},"reference-count":35,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,5]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Although initial therapy of mantle cell lymphoma (MCL) is not standardized, bendamustine plus rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance after induction is often used. Thus, the open-label, randomized phase 2 ECOG-ACRIN Cancer Research Group E1411 trial was designed to test 2 questions: (1) does addition of bortezomib to BR induction (BVR) and\/or (2) addition of lenalidomide to rituximab (LR) maintenance improve progression-free survival (PFS) in patients with treatment-na\u00efve MCL? From 2012 to 2016, 373 previously untreated patients, 87% aged \u226560 years, were enrolled in this trial. At a median follow-up of 7.5 years, there is no difference in the median PFS of BR compared with BVR (5.5 vs 6.4 years; hazard ratio [HR], 0.90; 90% confidence interval [CI], 0.70-1.16). There were no unexpected additional toxicities with BVR treatment compared with BR, with no impact on total dose\/duration of treatment received. Independent of the induction treatment, addition of lenalidomide did not significantly improve PFS, with median PFS in R vs LR (5.9 vs 7.2 years; HR, 0.84; 90% CI, 0.62-1.15). Most patients completed the planned 24 cycles of LR at the scheduled dose. In summary, adding bortezomib to BR induction does not prolong PFS in treatment-na\u00efve MCL, and LR maintenance was not associated with longer PFS compared with R alone after BR. Nonetheless, the &amp;gt;5-year median PFS outcomes in this prospective cooperative group trial indicate the efficacy of BR followed by R maintenance as highly effective initial therapy for older patients with MCL. This trial was registered at www.clinicaltrials.gov as #NCT01415752.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024023962","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T19:55:03Z","timestamp":1717185303000},"page":"1083-1092","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Randomized study of induction with bendamustine-rituximab \u00b1 bortezomib and maintenance with rituximab \u00b1 lenalidomide for MCL"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1428-8765","authenticated-orcid":false,"given":"Mitchell R.","family":"Smith","sequence":"first","affiliation":[{"name":"1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1763-8214","authenticated-orcid":false,"given":"Opeyemi A.","family":"Jegede","sequence":"additional","affiliation":[{"name":"2Dana Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"3Meyer Cancer Center, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[{"name":"4Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir S.","family":"Parekh","sequence":"additional","affiliation":[{"name":"5Division of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9488-1704","authenticated-orcid":false,"given":"David T.","family":"Yang","sequence":"additional","affiliation":[{"name":"6Department of Pathology and Laboratory Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8623-4067","authenticated-orcid":false,"given":"Eric D.","family":"Hsi","sequence":"additional","affiliation":[{"name":"7Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas","family":"Witzig","sequence":"additional","affiliation":[{"name":"7Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Dave","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Duke University Medical Center, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David","family":"Scott","sequence":"additional","affiliation":[{"name":"9BC Cancer Agency-Vancouver Cancer Centre, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis","family":"Hanson","sequence":"additional","affiliation":[{"name":"7Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lale","family":"Kostakoglu Shields","sequence":"additional","affiliation":[{"name":"10Department of Radiology, NYU Langone Health-Perlmutter Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizar","family":"Abdel-Samad","sequence":"additional","affiliation":[{"name":"11The Moncton Hospital, Moncton, NB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-9932","authenticated-orcid":false,"given":"Carla","family":"Casulo","sequence":"additional","affiliation":[{"name":"12University of Rochester Medical Center-James P. Wilmot Cancer Center, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"13Washington University School of Medicine St. Louis and Siteman Cancer Center, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[{"name":"14Case Comprehensive Cancer Center, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tareq","family":"Al Baghdadi","sequence":"additional","affiliation":[{"name":"15St. Joseph Mercy Hospital, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristie A.","family":"Blum","sequence":"additional","affiliation":[{"name":"16The Arthur G. James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Romer","sequence":"additional","affiliation":[{"name":"17Good Samaritan Hospital-Dayton, Kettering, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Inwards","sequence":"additional","affiliation":[{"name":"7Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel E.","family":"Lerner","sequence":"additional","affiliation":[{"name":"18Frauenshuh Cancer Center and Park Nicollet Institute, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9685-4796","authenticated-orcid":false,"given":"Lynne I.","family":"Wagner","sequence":"additional","affiliation":[{"name":"19The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4091-1699","authenticated-orcid":false,"given":"Richard F.","family":"Little","sequence":"additional","affiliation":[{"name":"20Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"12University of Rochester Medical Center-James P. Wilmot Cancer Center, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"3Meyer Cancer Center, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-6609","authenticated-orcid":false,"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"13Washington University School of Medicine St. Louis and Siteman Cancer Center, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"26","key":"2024090515205466800_bib1","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2024090515205466800_bib2","unstructured":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) for B-cell lymphoma version 6.2023. Accessed 1 September 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"issue":"3","key":"2024090515205466800_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"9873","key":"2024090515205466800_bib4","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"2024090515205466800_bib5","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2024090515205466800_bib6","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024090515205466800_bib7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024090515205466800_bib8","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2024090515205466800_bib9","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","article-title":"Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study","volume":"29","author":"Fowler","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024090515205466800_bib10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/leu.2016.305","article-title":"Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499","volume":"31","author":"Smith","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"2024090515205466800_bib11","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)","volume":"123","author":"Chang","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2024090515205466800_bib12","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2013.088377","article-title":"First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group","volume":"98","author":"Arranz","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"2024090515205466800_bib13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2024090515205466800_bib14","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024090515205466800_bib15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical\u00a0trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"10","key":"2024090515205466800_bib16","doi-asserted-by":"crossref","first-page":"E575","DOI":"10.1002\/ajh.24854","article-title":"Long-term analysis of phase II studies of single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma","volume":"92","author":"Witzig","year":"2017","journal-title":"Am J Hematol"},{"issue":"19","key":"2024090515205466800_bib17","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"issue":"20","key":"2024090515205466800_bib18","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1182\/bloodadvances.2019000526","article-title":"Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma","volume":"3","author":"Kamdar","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2024090515205466800_bib19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2024090515205466800_bib20","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood.V112.11.2596.2596","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab in the first-line-treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the study group indolent lymphomas (StiL)","volume":"112","author":"Rummel","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2024090515205466800_bib21","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024090515205466800_bib22","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"2024090515205466800_bib23","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/s41375-024-02254-2","article-title":"The addition of bortezomib to rituximab, high dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma: a randomized open-label phase 3 trial of the European MCL Network","volume":"38","author":"Fischer","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"2024090515205466800_bib24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/10428194.2017.1321750","article-title":"Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study","volume":"60","author":"Robak","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2024090515205466800_bib25","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1182\/blood.2021014270","article-title":"Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma","volume":"140","author":"Ferrero","year":"2022","journal-title":"Blood"},{"issue":"suppl 15","key":"2024090515205466800_bib26","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","article-title":"Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (BR) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial) [abstract]","volume":"34","author":"Rummel","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2024090515205466800_bib27","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/bloodadvances.2023009744","article-title":"Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL","volume":"7","author":"Tisi","year":"2023","journal-title":"Blood Adv"},{"issue":"23","key":"2024090515205466800_bib28","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with Obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2024090515205466800_bib29","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024090515205466800_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2022-163018","article-title":"Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network [abstract]","volume":"140","author":"Dreyling","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024090515205466800_bib31","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1182\/blood-2021-153390","article-title":"Ibrutinib plus rituximab and venetoclax (IRV) followed by risk-stratified observation or short course R-hypercvad\/MTX in young patients with previously untreated mantle cell lymphoma-phase-II window-2 clinical trial [abstract]","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024090515205466800_bib32","article-title":"Six years follow up of ibrutinib plus rituximab (IR) followed by short course R-hyper CVAD\/MTX in patients (age \u2264 65 years) with previously untreated mantle cell lymphoma - phase-II window-1 clinical trial [abstract]","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2024090515205466800_bib33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024090515205466800_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood-2022-158656","article-title":"Phase 2 trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-naive mantle cell lymphoma [abstract]","volume":"140","author":"Ruan","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024090515205466800_bib35","article-title":"A\u00a0multicenter phase 2 trial of Zanubrutinib, Obinutuzumab, and venetoclax (BOVen) in patients with treatment-na\u00efve, TP53-mutant mantle cell lymphoma [abstract]","volume":"142","author":"Kumar","year":"2023","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/10\/1083\/2240694\/blood_bld-2024-023962-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/10\/1083\/2240694\/blood_bld-2024-023962-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:40:23Z","timestamp":1725550823000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/10\/1083\/516345\/Randomized-study-of-induction-with-bendamustine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,9,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024023962","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]}}}